-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Benzinga·08/14/2026 14:18:44
Listen to the news
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.